Stockwinners Market Radar for October 04, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

22:15 EDT Vista Outdoor to sell Revelyst for $1.125B, amends agreement to acquire Kinetic - Vista Outdoor "announced it has entered into a definitive agreement with funds managed by Strategic Value Partners, LLC, and its affiliates, a global alternative investment firm with approximately $19B of assets under management, to sell Revelyst in an all-cash transaction based on an enterprise value of $1.125B. In connection with the SVP Transaction, Vista Outdoor also entered into an amendment to the merger agreement with Czechoslovak Group a.s. to acquire The Kinetic Group, increasing the purchase price for the Kinetic Group to $2.225B. The SVP Transaction has been unanimously approved by the Board and is expected to close by January 2025, subject to the completion of the CSG Transaction, as well as the receipt of necessary regulatory approvals and other customary closing conditions. Vista Outdoor and CSG have received all regulatory approvals required under the merger agreement for the CSG Transaction and are prepared to close the CSG Transaction prior to the end of 2024, subject to receipt of stockholder approval and satisfaction of other customary closing conditions. CSG and Vista Outdoor have mutually agreed to extend the termination date of the CSG merger agreement to December 11, 2024. The SVP Transaction is subject to the completion of the CSG Transaction. Together, the CSG Transaction and the SVP Transaction represent an enterprise value of $3.35B for Vista Outdoor and will deliver an estimated $45 per share in cash to Vista Outdoor stockholders. The SVP Transaction has been unanimously approved by the Board and is expected to close by January 2025, subject to the completion of the CSG Transaction, as well as the receipt of necessary regulatory approvals and other customary closing conditions. Vista Outdoor and CSG have received all regulatory approvals required under the merger agreement for the CSG Transaction and are prepared to close the CSG Transaction prior to the end of 2024, subject to receipt of stockholder approval and satisfaction of other customary closing conditions. CSG and Vista Outdoor have mutually agreed to extend the termination date of the CSG merger agreement to December 11, 2024. At the closing of the CSG Transaction, CSG will pay the Company $2.225 billion, subject to certain purchase price adjustments, and Vista Outdoor stockholders will receive $25.75 in cash per Vista Outdoor share and one share of Revelyst common stock for each share of Vista Outdoor common stock. At the closing of the SVP Transaction, SVP will pay Revelyst stockholders an aggregate of $1.125 billion, subject to a net cash adjustment, representing an estimated $19.25 in cash per share of Revelyst common stock, based on current management estimates of expected net cash of Revelyst as of the closing of the SVP Transaction. "

21:36 EDT MongoDB CEO sells $911K in common stock - In a regulatory filing, MongoDB disclosed that its CEO Dev Ittycheria sold 3,556 shares of common stock on October 2nd in a total transaction size of $911K.

17:49 EDT Zoom Video CFO Steckelberg sells 8,901 common shares - In a regulatory filing, Zoom Video CFO Kelly Steckelberg disclosed the sale of 8,901 class A common shares of the company on October 2 at a price of $67.7942 per share.

17:25 EDT General Dynamics awarded $376.79M Navy contract modification - General Dynamics was awarded a $376.79M cost-plus-fixed-fee modification to a previously awarded contract for Lead Yard support, and development studies and design efforts related to Virginia Class submarines. Work is expected to be completed by October 2025. Naval Sea Systems Command is the contracting activity.

17:02 EDT Motorsport Games to consider strategic alternatives, reduce headcount - Motorsport Games announced that the board of directors has authorized management to consider strategic alternatives to maximize shareholder value, including a potential sale or merger of the company. Management is also seeking funding that would allow it to deliver on viable opportunities including bringing Le Mans Ultimate to Sony PlayStation and Microsoft Xbox gaming consoles. Le Mans Ultimate is the official game of the FIA World Endurance Championship and the 24 Hours of Le Mans and was released on PC platforms in early access in February 2024. Furthermore, the company has undergone a restructuring including headcount reductions that have been undertaken in its business as part of an ongoing initiative to reduce cash expenditure and further improve efficiency. As part of the restructuring, the company determined to implement additional measures to continue to bring down its year-over-year operating expense through a reduction of the company's workforce primarily in the United States and the United Kingdom.

16:31 EDT Bit Digital produces 51.5 bitcoin in September, up 3.6% from prior month - Bit Digital announced its unaudited digital asset production, HPC services revenue, and corporate updates for the month of September 2024. The Company had 256 servers actively generating revenue from its initial Bit Digital AI contract, as of September 30, 2024. The Company earned approximately $4.2 million of unaudited revenue from this contract during the month of September 2024. In September 2024, the Company produced 51.5 BTC, a 3.6% decrease compared to the prior month. The Company's active hash rate was approximately 2.43 EH/s as of September 30, 2024. Treasury holdings of BTC and ETH were 731.3 and 27,388.9 with a fair market value of approximately $46.3 million and $71.3 million, respectively, on September 30, 2024. The BTC equivalent of our digital asset holdings as of September 30, 2024, was approximately 1,863.0 or approximately $118.0 million. The Company had cash and cash equivalents of $104.0 million and total liquidity (defined as cash and cash equivalents, USDC, and the fair market value of digital assets) of approximately $222.0 million, as of September 30, 2024.

16:22 EDT Rio Tinto in discussions to acquire Arcadium Lithium, Reuters reports - Rio Tinto (RIO) has been having discussions to acquire lithium miner Arcadium (ALTM), a deal that would dmake Rio the third-biggest producer of the EV battery metal, Reuters' Ernest Scheyder and Clara Denina report, citing three sources with direct knowledge of the negotiations. Discussions have been ongoing and continued in London this week, the authors say. An offer is anticipated in the near future, though talks remain ongoing and may not necessarily lead to a deal, the authors note. Reference Link

16:10 EDT Psyence Biomedical will not proceed with Clairvoyant Therapeutics acquisition - Psyence Biomedical provided an update on its previously announced proposed acquisition of Clairvoyant Therapeutics. Following the completion of necessary due diligence and other pre-closing activities specified in the conditional binding term sheet that was announced on September 9, Psyence Biomed has decided not to proceed with the acquisition at this time. Psyence Biomed continues to advance its recently initiated Phase IIb clinical trial of nature derived psilocybin in conjunction with psychotherapy as a potential treatment for Adjustment Disorder following a life-limiting cancer diagnosis in Palliative Care. The first patient is expected to be randomized into the study this quarter, and topline data from the study is anticipated in the second half of 2025. Additionally, the company is progressing its second development program, which will evaluate nature derived psilocybin in conjunction with psychotherapy as a potential treatment for Substance Use Disorders, leading with Alcohol Use Disorder. To support its AUD program, Psyence Biomed recently announced a worldwide, exclusive royalty-bearing IP licensing agreement with PsyLabs, a private company focused on the production of highly purified psychedelic active pharmaceutical ingredients and extracts. Psyence Biomed also subsequently agreed to acquire an 11.13% stake in Psylabs as it evolves into a leading, vertically integrated developer of psychedelic-based therapeutics. Due diligence is ongoing, and Psyence Biomed plans to issue a further update on this pending acquisition shortly.

16:07 EDT D-Wave Quantum receives noncompliance notice from NYSE - D-Wave Quantum announced that it received notice from the NYSE that it is not in compliance with Section 802.01C of the NYSE Listed Company Manual because, as of October 2, the average closing price of the company's common stock was less than $1.00 over a consecutive 30 trading-day period. The notice does not result in the immediate delisting of the Company's common stock from the NYSE.

16:06 EDT Trevena receives Nasdaq delisting notification - Trevena announced that on October 4, 2024 the company received notice that the Nasdaq Hearings Panel had determined to delist the company's common stock from The Nasdaq Stock Market LLC due to the company's failure to comply with the minimum stockholder's equity requirement under Nasdaq Listing Rule 5550(b)(1). As previously disclosed, the Panel had provided the company until October 2, 2024, to regain compliance with the Equity Standard Rule.

16:03 EDT Altamira Therapeutics provides update on Nasdaq listing - Altamira Therapeutics announced that it received on September 30, 2024, a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC that it no longer complied with Rule 5550(a)(2) of Nasdaq's Listing Rules, which requires listed securities to maintain a minimum bid price of $1.00 per share, because the bid price of the company's listed securities has closed at less than $1.00 per share over the previous 30 consecutive business days, from August 16, 2024 through September 27, 2024. The letter stated that the Company is not eligible for any cure period due to the fact that the Company effectuated one or more reverse stock splits over the prior two-year period with a cumulative ratio of 250 shares or more to one. The company intends to appeal this determination to a hearing panel. The hearing request will result in a stay of any suspension or delisting action pending the hearing. There can be no assurance that the Panel will grant the company's request for continued listing or that any extension will be granted by the Panel.

14:51 EDT FAA accepts Delta's plan to use drones for maintenance inspections - The FAA recently accepted Delta's application to utilize camera-based, small drones to conduct visual inspections of our aircraft in the operation. Delta TechOps was granted this acceptance earlier this year and has thoughtfully been implementing drone inspections into our maintenance processes. These conditional visual inspections will initially be used following lightning strike events, and the use of drone inspections has been added to the Aircraft Maintenance Manual for Delta's entire mainline fleet. Delta is the first U.S. commercial operator to receive FAA Certificate Management Office concurrence for its plans to use these drones for maintenance inspections across its fleet.

13:01 EDT Baker Hughes reports U.S. rig count down 2 to 585 rigs - Baker Hughes reports that the U.S. rig count is down 2 from last week to 585 with oil rigs down 5 to 479, gas rigs up 3 to 102 and miscellaneous rigs unchanged at 4. The U.S. Rig Count is down 34 rigs from last year's count of 619 with oil rigs down 18, gas rigs down 16 and miscellaneous rigs unchanged. The U.S. Offshore Rig Count is down 1 to 18, down 2 year-over-year. The Canada Rig Count is up 5 from last week to 223, with oil rigs up 5 to 157, gas rigs down 2 to 63 and miscellaneous rigs up 2 to 3. The Canada Rig Count is up 43 from last year's count of 180, with oil rigs up 49, gas rigs down 9 and miscellaneous rigs up 3.

12:31 EDT KalVista presents data showing sebetralstat effectiveness in reducing anxiety - KalVista Pharmaceuticals announced that it presented data showing the effectiveness of sebetralstat in reducing anxiety among people experiencing hereditary angioedema attacks at the HAEi Global Angioedema Forum taking place in Copenhagen, Denmark, October 4 - 5, 2024. These data were generated in the KONFIDENT phase 3 clinical trial, for which the company disclosed top line results in February 2024. Sebetralstat is a novel, investigational oral plasma kallikrein inhibitor for the on-demand treatment of HAE attacks in adults and adolescents aged 12 years and older. KONFIDENT was the first randomized controlled trial to assess the impact of an on-demand treatment on anxiety associated with HAE attacks. This prespecified exploratory analysis was presented by Dr. William R. Lumry, AARA Research Center, Dallas, TX, USA and investigated attack-associated anxiety in the phase 3 KONFIDENT trial and the impact of sebetralstat on anxiety, compared with placebo. Participants self-reported anxiety using a Modified Generalized Anxiety Numeric Rating Scale. Overall, anxiety was reduced among patients treated with sebetralstat 300mg and 600mg versus placebo. For participants with moderate-to-extreme anxiety, change from baseline at 4 hours was -2.8 for each sebetralstat group and -1.3 for placebo and at 12 hours was -3.5 with sebetralstat 300mg, -4.3 with 600mg, and -1.7 with placebo. Notably, anxiety reduction was correlated with earlier time to beginning of symptom relief. "The data presented at the Global Angioedema Forum highlights that people living with HAE often experience substantial anxiety when they have attacks, which reduces quality of life. In KONFIDENT, oral sebetralstat significantly reduced anxiety during attacks compared with placebo, especially among participants with moderate-to-extreme anxiety," said William Lumry, M.D., Allergy and Asthma Research Associates, Dallas, Texas, United States.

12:10 EDT Skyx jumps 7% to 88c after announcing Home Depot availability

12:00 EDT Coeur Mining falls -7.0% - Coeur Mining is down -7.0%, or -49c to $6.58.

12:00 EDT ZIM Integrated falls -14.2% - ZIM Integrated is down -14.2%, or -$3.07 to $18.60.

12:00 EDT Beyond rises 13.2% - Beyond is up 13.2%, or $1.22 to $10.41.

11:57 EDT Prime Medicine granted orphan status for glycogen storage disease - The FDA granted Prime Medicine orphan status for its treatment of glycogen storage disease type 1B. Reference Link

11:24 EDT Chain Bridge Bancorp opens at $22, IPO priced at $22 per share - Chain Bridge Bancorp, the bank holding company for Chain Bridge Bank, National Association, priced its initial public offering of 1.85M shares of its Class A common stock at a public offering price of $22.00 per share. The shares began trading on the New York Stock Exchange under the ticker symbol "CBNA". Piper Sandler, Raymond James and Hovde Group acted as joint book running managers for the offering.

10:35 EDT Uxin Ltd trading resumes

10:14 EDT IRS announces Direct File set to expand availability for 2025 tax season - The Internal Revenue Service announced that Direct File will be available for the 2025 tax filing season in double the number of states than last year's pilot, and it will cover a wider range of tax situations, greatly expanding the number of taxpayers eligible to use the free e-filing service. "For the 2025 tax filing season, eligible taxpayers in 24 states will be able to use Direct File: 12 states that were part of the pilot last year, plus 12 new states where Direct File will be available in the upcoming filing season. During the pilot last year, Direct File was available in Arizona, California, Florida, Massachusetts, Nevada, New Hampshire, New York, South Dakota, Tennessee, Texas, Washington State and Wyoming. For the 2025 tax filing season, Direct File will also be available in Alaska, Connecticut, Idaho, Kansas, Maine, Maryland, New Jersey, New Mexico, North Carolina, Oregon, Pennsylvania and Wisconsin. In 2025, more than 30 million taxpayers in those 24 states will be eligible to use Direct File. Additional states could still join Direct File in 2025, and several states have expressed interest or announced that they will participate in Direct File in 2026," the IRS stated. Publicly-traded companies offering tax preparation services include Intuit (INTU) and H&R Block (HRB). Reference Link

10:00 EDT Arcadium Lithium rises 9.5% - Arcadium Lithium is up 9.5%, or 27c to $3.06.

10:00 EDT Barnes Group rises 10.2% - Barnes Group is up 10.2%, or $4.08 to $44.14.

10:00 EDT AMTD Digital falls -8.0% - AMTD Digital is down -8.0%, or -42c to $4.80.

09:57 EDT NASB Financial CEO Thomas Wagers to retire, Enrique Venegas to succeed - NASB Financial announced that its CEO Thomas Wagers will be retiring from his position of CEO following its annual stockholders meeting in January 2025. Mr. Wagers will remain as a member of the Board of Directors of both NASB Financial and its banking subsidiary North American Savings Bank following his retirement. The Company has appointed Enrique Venegas to succeed Mr. Wagers as CEO following Mr. Wagers' retirement, and Mr. Venegas has been named President of both NASB Financial and North American Savings Bank, effective October 1, 2024. Mr. Venegas has also been appointed to the Board of both NASB Financial and North American Savings Bank. Prior to his appointment, Mr. Venegas was NASB's EVP and Chief Lending Officer.

09:49 EDT Arcadium Lithium rises 7.9% - Arcadium Lithium is up 7.9%, or 22c to $3.02.

09:48 EDT Barnes Group rises 10.1% - Barnes Group is up 10.1%, or $4.07 to $44.12.

09:47 EDT Coeur Mining falls -11.6% - Coeur Mining is down -11.6%, or -82c to $6.26.

09:38 EDT Learn CW Investment Corp trading resumes

09:33 EDT Learn CW Investment Corp trading halted, volatility trading pause

09:31 EDT Tempur Sealy files case to enjoin FTC's administrative merger challenge

09:17 EDT CCC Intelligent Solutions reports retirement of CSDO, departure of CCCSO - In a regulatory filing, CCC Intelligent Solutions Holdings announced the retirement of Mary Jo Prigge and the departure of Michael Silva. Mary Jo Prigge, Executive Vice President, Chief Service Delivery Officer of the company notified the company that she will retire from her role with the company no later than December 31, and the firm expects that, following her retirement from this role, Ms. Prigge will continue in a part-time advisory capacity to senior management. Michael Silva, Executive Vice President, Chief Commercial & Customer Success Officer of the company will be departing the company due to role elimination effective no later than December 31, 2024. "As a result, the company is consolidating their roles in order to streamline its operations in continued support of its customers and to deliver on our expected long-term growth. An executive search has been initiated to find a leader for this new consolidated role," the filing stated. Reference Link

09:15 EDT MSG family of companies expands partnership with Verizon - Madison Square Garden Entertainment (MSGE), Madison Square Garden Sports Corp. (MSGS) and Sphere Entertainment (SPHR) announced an expanded partnership with Verizon (VZ), naming America's leading telecommunications company the Official Mobile Wireless Partner across the MSG Family of Companies. This first-of-its-kind integrated marketing partnership provides exposure for Verizon across the MSG Family of Companies' portfolio of premier sports and entertainment assets, which includes New York's Madison Square Garden, Radio City Music Hall, The Theater at Madison Square Garden, Beacon Theatre; The Chicago Theatre; Sphere in Las Vegas; the New York Knicks, New York Rangers and Westchester Knicks professional sports franchises; the Christmas Spectacular Starring the Radio City Rockettes; and MSG Networks.

09:07 EDT DMG Blockchain Solutions reports 23 bitcoin mined in September - DMG Blockchain Solutions announces its preliminary Bitcoin operational results for September 2024: Bitcoin Mined: 23 BTC; Hashrate: 1.1 EH/s; Bitcoin Holdings: 436 BTC; Hosting Update: DMG is in the process of transitioning approximately 0.15 EH/s of its mining fleet to a third-party hosting provider in Canada, further enhancing operational flexibility. As of the end of September, DMG has successfully energized its Bitmain T21 mining fleet, fully integrating it into its operations. This energization marks a key milestone in DMG's ongoing efforts to scale its mining infrastructure. Including the miners being hosted externally, DMG's current operating hashrate is approximately 1.6 EH/s. The Company is also focused on fleet optimization and remains on track to reach its near-term goal of 1.7 EH/s. These steps are part of DMG's broader strategy to maximize its operational efficiency while enhancing Bitcoin production.

09:05 EDT Territorial Bancorp postpones Special Meeting of Stockholders - Territorial Bancorp (TBNK) has postponed the Company's Special Meeting of Stockholders to vote on its proposed merger with Hope Bancorp (HOPE), which was originally scheduled for 8:30 a.m., Hawaii time, on October 10, 2024. The Special Meeting has been rescheduled for November 6, 2024 at 8:30 a.m., Hawaii time. The August 14, 2024 record date for stockholders entitled to vote at the Special Meeting is unchanged. The Special Meeting has been postponed in order to allow the Territorial Board of Directors and management team to continue discussions with stockholders regarding the pending Hope Bancorp merger. The Territorial Board continues to unanimously recommend that Territorial stockholders vote "For" the merger with Hope Bancorp and all related proposals.

09:03 EDT Alpha Star Acquisition receives non-compliance notice from Nasdaq - Alpha Star Acquisition received a letter from the Listing Qualifications Department of the Nasdaq Stock Market indicating that the Company is currently not in compliance with the minimum Market Value of Listed Securities set forth in the Nasdaq Listing Rules for continued listing on the Nasdaq Global Market. Nasdaq Listing Rule 5450(b)(2)(A) requires companies to maintain a minimum MVLS of $50,000,000 and Nasdaq Listing Rule 5810(c)(3)(C) provides that a failure to meet the MVLS requirement exists if the deficiency continues for a period of 30 consecutive business days. Based on the MVLS of the Company from August 12, 2024 to September 30, 2024, the Company no longer meets the minimum MVLS requirement. This notification does not impact the listing and trading of the Company's securities at this time. Pursuant to Nasdaq Listing Rule 5810(c)(3)(C), the Company has been provided a compliance period of 180 calendar days, or until March 31, 2025, to regain compliance with the Rule. To regain compliance, the Company's MVLS must meet or exceed $50,000,000 for a minimum of ten consecutive business days prior to March 31, 2025. If at any time during this compliance period the Company's MVLS closes at $50,000,000 or more for a minimum of ten consecutive business days, Nasdaq will provide the Company with written confirmation of compliance and the matter will be closed. In the event the Company fails to timely regain compliance with the Rule, the Company's securities will be subject to delisting from Nasdaq. Alternatively, the Company may consider applying for a transfer to the Nasdaq Capital Market. The Company intends to regain compliance with the applicable Nasdaq Listing Rules and will evaluate its available options to regain compliance with the MVLS Requirement within the 180-calendar-day compliance period.

08:47 EDT Orbit's Power Group reports September bookings in excess of $1.8M - Orbit International announced that bookings for its Orbit Power Group for the month of September 2024 were in excess of $1,800,000, giving it total bookings for the third quarter in excess of $2,800,000. Deliveries for these orders have already commenced and are expected to continue through the fourth quarter of 2025. Bookings for the month of September were highlighted by a follow-on order for a COTS power supply, for approximately $1,450,000, that are used for nuclear power plants. In addition, OPG bookings continued for its VPX power supplies during the quarter. Other orders were for additional COTS and commercial power supplies.

08:36 EDT Biodexa provides update on PFS, OS in Phase 1 study of MTX110 in rGBM - Biodexa Pharmaceuticals announces an update in respect of its open label Phase 1 study of MTX110 in recurrent glioblastoma. In October 2023, the Company announced completed recruitment of four patients into cohort A of its Phase 1 study of MTX110 in patients with recurrent glioblastoma. MAGIC-G1 is an open-label, dose escalation study designed to assess the feasibility and safety of intermittent infusions of MTX110 administered by convection enhanced delivery via implanted refillable pump and catheter. Patients received MTX110 via intermittent repeated CED infusions. As of today, the status of patients in Cohort A is as follows: Patients #1 and #2 have deceased with overall survival since start of treatment of 12 months and 13 months, respectively. Patients #3 and #4 remain in post-study follow-up. Patient #3 had progression free survival of six months and OS thus far of 13 months since start of treatment. Patient #4 has not yet had confirmed progression and, as of today, has PFS and OS of 12 months since start of treatment. These interim data in rGBM build on the data announced by the Company on July 2, 2024, and presented at the recent 21st International Symposium on Paediatric Neuro-Oncology of a Phase 1 study of MTX110 in nine patients with Diffuse Midline Glioma which showed, after only two infusions and a single patient at optimum dose, median OS of 16.5 months. In an earlier Phase 1 study conducted by the University of California San Francisco of MTX110 in seven patients with DMG which showed median OS of 26.1 months. These data compare favorably with median OS in a cohort of 316 cases of 10.0 months.

08:33 EDT Sonnet BioTherapeutics receives funding through NJEDA, Australia tax programs - Sonnet BioTherapeutics has received preliminary approval for a tax credit from the New Jersey Technology Business Tax Certificate Transfer Program administered by the New Jersey Economic Development Authority. Sonnet received approval of its application to sell up to $8,143,144 of its New Jersey State net operating losses and $62,810 of its New Jersey State research and development tax credits for proceeds of up to $0.795M through the New Jersey Technology Business Tax Certificate Transfer Program, subject to execution of such sale. Sonnet also expects to receive a $0.7M net cash refund from the R&D Tax Incentive Program in Australia. The Technology Business Tax Certificate Transfer Program administered by the NJEDA enables qualified companies to sell up to $20M of their unused New Jersey NOLs and R&D tax credits to unaffiliated, profit-generating corporate taxpayers in the State of New Jersey. The Technology Business Tax Certificate Transfer Program is designed to allow technology and biotechnology companies with NOLs to turn their tax losses and credits into cash proceeds to fund more R&D, expand its workforce and cover other allowable expenditures. Sonnet is one of several biotechnology/technology companies to qualify in this competitive process to share in the funding this year. The Australian R&D Tax Incentive Program allows certain companies to claim a significant percentage of their costs related to R&D activities they have or are planning to undertake in Australia. The Company expects to receive the Australian net cash refund before calendar year end 2024 and the proceeds from the sale of its New Jersey NOLs and R&D tax credits before the end of the first calendar quarter of 2025, subject to execution of such sale.

08:18 EDT Verisk Analytics announces U.S. launch of Whitespace - Verisk announced the U.S. launch of Whitespace, an all-in-one intuitive platform which enables brokers, underwriters and managing general agents to offer, negotiate and place business in the global (re)insurance market. The only truly digital platform of its kind, Whitespace caters to different business classes and geographical regions, now including U.S.- based brokers, wholesalers, carriers and risks. This expansion builds on the success of Whitespace in the London market, where nearly 170,000 lines have been written to date in 2024 - more than triple the amount written in 2022.

08:06 EDT TeraWulf mines 176 bitcoin in September - September 2024 Production and Operations Highlights: Self-Mined Bitcoin: TeraWulf mined 176 bitcoin in September, achieving an average production rate of approximately 5.9 bitcoin per day. Operating Capacity: The Company's operational self-mining capacity remained at approximately 10.0 EH/s, representing a 100.0% increase year-over-year. Power Cost: The average power cost per bitcoin mined was $35,109 in September, corresponding to an approximate rate of $0.042/kWh. This figure excludes anticipated proceeds from demand response and ancillary services. "During September, TeraWulf mined 176 bitcoin, maintaining an average production rate of approximately 6 bitcoin per day," said Sean Farrell, Senior Vice President of Operations at TeraWulf. "We are currently implementing large-scale PSU replacements and ventilation upgrades in miner building 3, "MB-3", to enhance performance as cooler fall temperatures arrive. The recent sale of our equity interest in Nautilus has provided significant capital to accelerate the expansion of our HPC and AI data center at Lake Mariner. This strategic reinvestment strengthens our ongoing initiatives, including the successful completion of our 2 MW 'WULF Den' proof-of-concept for WULF Compute, designed for high-density GPU workloads. Construction of CB-1, our 20 MW HPC/AI facility at Lake Mariner, is on track, with completion expected in Q1 2025. We've also secured long-lead items for CB-2, a 50 MW AI/HPC facility, to ensure timely completion in early Q2 2025."

08:03 EDT YY Group anounces partnership with Dian Xiao Er Group - YY Group Holding announced a strategic partnership with Dian Xiao Er Group. This collaboration will support all 17 Dian Xiao Er outlets in Singapore. With YY Circle's staffing solution, Dian Xiao Er is set to scale efficiently while maintaining its world-class service and culinary excellence.

08:02 EDT Taysha Gene Therapies announces inducement grant under Nasdaq listing rule - Taysha Gene Therapies announced that, on October 1, 2024, the Compensation Committee of Taysha's Board of Directors granted one new employee an option to purchase 501,600 shares of the Company's common stock in connection with their employment. The stock option was granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individual entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4). The stock option has an exercise price of $2.02 per share, which is equal to the closing price of Taysha's common stock on the date of grant. The stock option has a 10-year term and will vest over four years, with 25% of the option vesting on the first anniversary of the vesting commencement date and the remaining 75% of the option vesting in equal monthly installments over the 36 months thereafter. Vesting of the stock option is subject to such employee's continued service to Taysha on each vesting date.

08:00 EDT Insmed reports inducement grants under NASDAQ listing rule - Insmed Incorporated announced the granting of inducement awards to 52 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.

07:47 EDT Spirit Airlines sinks 37% to $1.41 after WSJ report of bankruptcy talks

07:17 EDT Coeur Mining announces the acquisition of SilverCrest Metals - Coeur Mining (CDE) and SilverCrest Metals (SILV) announce that they have entered into a definitive agreement whereby, a wholly-owned subsidiary of Coeur will acquire all of the issued and outstanding shares of SilverCrest pursuant to a court-approved plan of arrangement. Under the terms of the Agreement, SilverCrest shareholders will receive 1.6022 Coeur common shares for each SilverCrest common share. The Exchange Ratio implies consideration of $11.34 per SilverCrest common share, based on the closing price of Coeur common shares on the New York Stock Exchange on October 3, 2024. This represents an 18% premium based on 20-day volume-weighted average prices of Coeur and SilverCrest each as at October 3, 2024 on the NYSE and NYSE American, respectively, and a 22% premium to the October 3, 2024 closing price of SilverCrest on the NYSE American. This implies a total equity value of approximately $1.7 billion based on SilverCrest's common shares outstanding. Upon completion of the Transaction, existing Coeur stockholders and SilverCrest shareholders will own approximately 63% and 37% of the outstanding common stock of the combined company, respectively.

07:06 EDT Oncolytics announces upcoming milestones - Anticipated upcoming milestones: H1 2025: Initiate registrational study of pelareorep + paclitaxel in HR+/HER2- metastatic breast cancer; H1 2025: Safety run-in data from cohort 5 of the GOBLET study, investigating pelareorep and mFOLFIRINOX with or without atezolizumab in newly diagnosed pancreatic cancer; H1 2025: updated efficacy data from cohort 4 of the GOBLET study, investigating pelareorep and atezolizumab in second-line or later anal cancer; H2 2025: Initial efficacy results from cohort 5 of the GOBLET study, investigating pelareorep and mFOLFIRINOX with or without atezolizumab in newly diagnosed pancreatic cancer

07:06 EDT Cartesian Therapeutics announces employment inducement grant - Cartesian Therapeutics announced the granting of inducement awards to five new employees. On October 1, 2024, the Company issued to these employees options to purchase an aggregate of 60,961 shares of the Company's common stock with an exercise price of $17.11, the closing trading price of the Company's common stock on the Nasdaq Global Market on the date of grant. The options were granted pursuant to the Company's Amended and Restated 2018 Employment Inducement Incentive Award Plan and were approved by the Company's board of directors. The option vests as to 25% on October 1, 2025, and then in three equal annual installments thereafter such that the options will be fully vested on October 1, 2028. The options have a ten-year term. The options were granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement material to the employees' entry into employment with the Company.

07:04 EDT Emerita Resources sponsors Sustainable International Mining Summit - Emerita Resources announced its sponsorship of the inaugural Sustainable International Mining Summit on October 10, 2024, taking place in the Guadiana Eurocity of Ayamonte, in the province of Huelva, Spain. This event, hosted by Global Omnium, a leading sustainability-focused company in Spain and across Europe, and strategic partner of the Company, aims to foster dialogue and collaboration between industry leaders, policymakers, and local communities on sustainable mining practices, highlighting the essential role of mining in the energy transition. The SIM Summit will feature a comprehensive agenda divided into three dynamic topics, Environmental, Social, and Governance practices, showcasing international speakers from European and Canadian institutions, and renowned experts from various industrial sectors. Participants will engage in discussions surrounding innovative sustainability initiatives, regulatory frameworks, and cutting-edge technologies that can drive the mining industry towards a more sustainable future.

07:03 EDT Laser Photonics, Fonon receives order for DTMR-3040 laser cleaning system - Laser Photonics in partnership with Fonon Technologies, announced that it has received an order for the DTMR-3040 laser cleaning system through ADS, a military equipment and logistics powerhouse, for a California-based Marine Corps Aviation Logistics Squadron, or MALS. The DefenseTech MRLS Roughening Laser is a laser system for handheld laser material processing. This system integrates a high-power continuous wave laser with dual axis release technology for tackling heavy duty decontamination and surface treatment tasks in MRO operations throughout the military.

07:02 EDT Lennar announces acquisition of 2,194 homesites within Caleb's Creek - Lennar announced the acquisition of 2,194 homesites within Caleb's Creek, to mark the latest addition to it's growing footprint in Winston-Salem, Kernersville, Greensboro, and the surrounding area. Spanning approximately 700 acres, Caleb's Creek will offer ten unique home collections including townhomes, ranch-style, and two-story homes, catering to a diverse range of homebuyers.

06:48 EDT Medtronic issues voluntary recall for MiniMed 600, 700 series insulin pumps - Medtronic voluntarily issued a field action starting on July 31, notifying global customers of its MiniMed 600 series or 700 series insulin pumps to follow their pump's built-in alerts and alarms for battery status and to contact Medtronic if they observe changes in the battery life of their pump. Medtronic began investigating this issue upon receiving customer reports of shortened battery life and an analysis found that pumps that have been dropped, bumped, or experienced physical impact even once may result in shortened battery life due to damage to internal electrical components. This electrical issue also causes battery alerts to occur when less battery life remains than the User Guide states. This may result in the pump stopping insulin delivery significantly sooner than usually expected and could lead to health risks like hyperglycemia or diabetic ketoacidosis, potentially requiring medical intervention. Most recently, Medtronic has received 170 reports of hyperglycemia greater than400mg/dL and 11 reports of diabetic ketoacidosis from January 2023 to September in the U.S. potentially related to this issue. The FDA has classified this action as a class I recall.

06:44 EDT Falco Resources announces Horne 5 project before BAPE - Falco Resources would like to thank the public, organizations and businesses that participated in the hearings of the Office of Public Hearings on the Environment that ended on October 3rd in the Anishinabeg community of the Long Point First Nation. During this second part of the public hearings, the many participants expressed their point of view on the Falco Horne 5 Project. More than 90 briefs were filed with the Commission of Inquiry, which offers participants the opportunity to make their voices heard and share their perspectives. Falco welcomes the support and commitment expressed by participants for the project, while taking into account the concerns raised and the recommendations made. Falco also welcomes the respectful and constructive climate in which the second part of the hearings took place, reflecting the collective commitment to the future of Rouyn-Noranda. Ultimately, this exercise helped to frame the challenges and opportunities associated with the project and Falco will now take the time to analyze all the memoirs. It will then bring together the Advisory Committee to discuss the issues raised and collectively identify possible solutions to improve its project to allow for harmonious development. Falco proposed several innovative initiatives that will allow for rigorous planning, aimed at minimizing the additional pressure on the surrounding environment. Falco noted that its proactive and collaborative approach was well received, and that many are already mobilizing to participate in the reflection. Taking its responsibilities seriously, Falco is determined to meet the expectations expressed, particularly with regard to the environment, the social and economic development of Rouyn-Noranda and will be ready to deliver a project that will meet its commitments. The BAPE report is due to be sent to the minister by December 26, 2024 and its publication is scheduled for mid-January 2025.

06:40 EDT Immuron says NMRC completes interim analysis for evaluation in Campylobacter - Following discussion with the US Naval Medical Research Command, Immuron can announce that the NMRC has completed the interim analysis for the clinical evaluation of a new oral therapeutic targeting Campylobacter and Enterotoxigenic Escherichia coli. The results of this clinical trial are unrelated to Travelan and do not impact Immuron's plans to hold an end of Phase 2 meeting with the U.S. Food and Drug Administration with a view to initiating Phase 3 clinical trial of Travelan in 2H 2025. Nor does this NMRC trial impact on Immuron's commercialization strategy for Travelan. This commercialization strategy also includes the results of the Uniformed Services University clinical study of Travelan which is 85% recruited with topline results anticipated in April 2025. The trial was funded by the NMRC. Immuron's involvement in the study was to produce a hyperimmune bovine colostrum product using the NMRC developed campylobacter/ETEC vaccine which was tested in a controlled human infection model study. Campylobacter jejuni is among the most common causes of diarrheal disease worldwide. Relatively little is known regarding what constitutes protective immunity against Campylobacter and there is currently no licensed vaccine to prevent disease caused by C. jejuni. C. jejuni is considered an invasive enteric pathogen, but the molecular details of its pathogenesis remain difficult to interpret or understand largely due to the lack of reliable, non-primate animal models of disease. To address this unmet medical need, the NMRC developed a conjugated vaccine using the Campylobacter jejuni capsule crosslinked to the colonization factor antigen 1 of Enterotoxigenic Escherichia coli. These key antigenic targets are predicted to be protective against diarrhea induced by both pathogens. Immuron used the conjugated vaccine to produce a new hyperimmune anti-microbial for clinical evaluation by the NMRC. The NMRC confirmed that the conjugated vaccine produced a robust immunological response in cows and reported that the new Hyper-immune therapeutic contains high levels of antibodies which specifically target Campylobacter jejuni capsule and CFA/1. Immuron has been advised by NMRC that the safety and protective efficacy of the product was tested in a controlled human infection-model clinical trial focusing on the ability of the hyperimmune product to protect volunteers against moderate to severe campylobacteriosis. A total of 27 volunteers were enrolled in the randomized, placebo-controlled trial and randomly assigned to either the active or placebo arm of the study. The interim results demonstrated 10.4% protective efficacy against moderate to severe campylobacteriosis following challenge with Campylobacter compared to the placebo group. Data analysis by the NRMC continues, including secondary and exploratory endpoints, which may provide insights as to why protective efficacy for CampETEC for was lower than that achieved in similar studies with Travelan. Immuron is not privy to any further details of the study at this time, pending the presentation of findings. Travelan(R) demonstrated clinical efficacy in preventing ETEC-attributable diarrhea in two previous CHIM studies. These studies showed dosing 400 mg three times daily, resulted in 76.7% to 90.9% protection and more recently 36.4% protective efficacy in a single daily dose Phase 2 study designed to compare the preventative effects of once daily dosing to the current standard recommended treatment of three times daily dosing. This Phase 2 single dose trial also produced clinically relevant secondary endpoints. The vaccine used in CampETEC was a conjugated vaccine for both campylobacter and ETEC. The NMRC recently received U.S. Department of Defense funding to develop a new campylobacter vaccine not conjugated with ETEC as well as new vaccines for shigella and different strains of E.coli. The plan is to develop new hyperimmune products which specifically target each of these pathogens in collaboration with Immuron. NRMC and Walter Reed Army Institute of Research are now developing an enhanced formulation of Travelan potentially expanding the coverage of the product as a therapeutic measure against endemic military relevant diarrheal pathogens

06:30 EDT Hive Digital announces 112 bitcoin produced in September - HIVE Digital Technologies announces its unaudited production results for September 2024. The company mined 112 Bitcoin, increasing its HODL portfolio by 1.4%, on a month over month basis, reaching a total of 2,604 BTC. HIVE maintained strong Bitcoin mining capacity, ending the month with 5.6 Exahash per second and an average capacity of over 5.3 EH/s, utilizing primarily hydroelectric power. Aydin Kilic, President and CEO, added, "Our primary focus is on upgrading our ASIC fleet, currently operating at 128 MW. Over the next six months, we'll be enhancing efficiency by replacing older ASICs with S21 Pro models. This upgrade is expected based on factors known today to lower our Bitcoin production cost to approximately $28,500 at current difficulty levels."

06:11 EDT Rivian Automotive revises annual production view to 47,000 - 49,000 vehicles - Rivian is experiencing a production disruption due to a shortage of a shared component on the R1 and RCV platforms. This supply shortage impact began in Q3 of this year, has become more acute in recent weeks and continues. As a result of the supply shortage, Rivian is revising its annual production guidance to be between 47,000 and 49,000 vehicles. The company is also reaffirming its annual delivery outlook of low single digit growth as compared to 2023, which it expects to be in a range of 50,500 to 52,000 vehicles.

06:05 EDT Hyundai, Waymo enter multi-year pact to integrate Waymo Driver into Ioniq 5 SUV - Hyundai Motor (HYMTF) and Waymo (GOOGL) announced they have entered into a multi-year, strategic partnership. In the first phase of this partnership, the companies will integrate Waymo's sixth generation fully autonomous technology - the Waymo Driver - into Hyundai's all-electric Ioniq 5 SUV, which will be added to the Waymo One fleet over time. The Ioniq 5 vehicles destined for the Waymo fleet will be assembled at the new Hyundai Motor Group Metaplant America EV manufacturing facility in Georgia and then integrated with Waymo's autonomous technology. The companies plan to produce a fleet of Ioniq 5s equipped with Waymo's technology in significant volume over multiple years to support Waymo One's growing scale. Initial on-road testing with Waymo-enabled Ioniq 5s will begin by late 2025 and become available to Waymo One riders in the years to follow. The Hyundai Ioniq 5 will be delivered to Waymo with specific autonomous-ready modifications like redundant hardware and power doors.

06:02 EDT Exact Sciences announces FDA approval of Cologuard Plus test - Exact Sciences announced the U.S. Food and Drug Administration approved the Cologuard Plus test, the company's next generation multitarget stool DNA test. The Cologuard Plus test is now approved for adults ages 45 and older who are average risk for colorectal cancer. FDA approval was based on findings from the pivotal BLUE-C study, one of the largest prospective, head-to-head studies ever conducted in CRC screening. Among the subset of nearly 19,000 average-risk participants, the Cologuard Plus test demonstrated 95% overall cancer sensitivity and 43% sensitivity for advanced precancerous lesions at 94% specificity with no findings on colonoscopy. Results from BLUE-C also show the Cologuard Plus test significantly outperformed an independent fecal immunochemical test for overall CRC sensitivity, treatable-stage CRC sensitivity, high-grade dysplasia sensitivity, and advanced precancerous lesion sensitivity.

05:06 EDT SolarBank to develop a 2.9 MW DC ground-mount solar power project - SolarBank announced its plans to develop a 2.9 MW DC ground-mount solar power project known as the Silver Springs project on a site located in Gainesville, New York. With a secured site lease and interconnection study underway, the project is another key addition to SolarBank's expanding development pipeline and presence in the region. Following the interconnection study, the company will continue to work to complete the permitting process and secure the necessary financing for the construction of the Project. The Project is expected to be eligible for incentives under the New York State Energy Research and Development Authority, or NYSERDA, NY-Sun Program. Once completed, the project will be operated as a community solar project. The clean energy generated by a community solar project feeds directly into the local electricity grid. Depending on the size and number of panels the project has, dozens or even hundreds of renters and homeowners can earn credits on their electric bill and save money from the electricity that is generated by the project. By subscribing to a project, community members can access the benefits of renewable energy without having to install panels on their home. There are several risks associated with the development of the project. The development of any project is subject to receipt of interconnection approval, required permits, the continued availability of third-party financing arrangements for the company and the risks associated with the construction of a solar power project. In addition, governments may revise, reduce or eliminate incentives and policy support schemes for solar power, which could result in future projects no longer being economic.